Chun-Geun Ryu, Eun-Joo Jung, Gangmi Kim, Su Ran Kim, Dae-Yong Hwang
{"title":"奥沙利铂所致肺纤维化2例报告","authors":"Chun-Geun Ryu, Eun-Joo Jung, Gangmi Kim, Su Ran Kim, Dae-Yong Hwang","doi":"10.3393/jksc.2011.27.5.266","DOIUrl":null,"url":null,"abstract":"<p><p>Oxaliplatin with infusional 5-fluorouracil plus leucovorin (FOLFOX regimen) is the one of the standard chemotherapy regimens for treating a colorectal carcinoma. The most common side effects include neutropenia, diarrhea, vomiting and peripheral neuropathy, and these are moderate and manageable. However, pulmonary toxicity is rarely reported to be associated with the FOLFOX regimen. Moreover, there is no established guideline for the management of this side effect. Here, along with a literature review, we report two cases of rapidly developing pulmonary fibrosis related to the use of the FOLFOX regimen in patients with colorectal carcinomas.</p>","PeriodicalId":17346,"journal":{"name":"Journal of the Korean Society of Coloproctology","volume":"27 5","pages":"266-9"},"PeriodicalIF":0.0000,"publicationDate":"2011-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d7/d7/jksc-27-266.PMC3218132.pdf","citationCount":"10","resultStr":"{\"title\":\"Oxaliplatin-induced Pulmonary Fibrosis: Two Case Reports.\",\"authors\":\"Chun-Geun Ryu, Eun-Joo Jung, Gangmi Kim, Su Ran Kim, Dae-Yong Hwang\",\"doi\":\"10.3393/jksc.2011.27.5.266\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Oxaliplatin with infusional 5-fluorouracil plus leucovorin (FOLFOX regimen) is the one of the standard chemotherapy regimens for treating a colorectal carcinoma. The most common side effects include neutropenia, diarrhea, vomiting and peripheral neuropathy, and these are moderate and manageable. However, pulmonary toxicity is rarely reported to be associated with the FOLFOX regimen. Moreover, there is no established guideline for the management of this side effect. Here, along with a literature review, we report two cases of rapidly developing pulmonary fibrosis related to the use of the FOLFOX regimen in patients with colorectal carcinomas.</p>\",\"PeriodicalId\":17346,\"journal\":{\"name\":\"Journal of the Korean Society of Coloproctology\",\"volume\":\"27 5\",\"pages\":\"266-9\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2011-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d7/d7/jksc-27-266.PMC3218132.pdf\",\"citationCount\":\"10\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of the Korean Society of Coloproctology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3393/jksc.2011.27.5.266\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2011/10/31 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the Korean Society of Coloproctology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3393/jksc.2011.27.5.266","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2011/10/31 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
Oxaliplatin-induced Pulmonary Fibrosis: Two Case Reports.
Oxaliplatin with infusional 5-fluorouracil plus leucovorin (FOLFOX regimen) is the one of the standard chemotherapy regimens for treating a colorectal carcinoma. The most common side effects include neutropenia, diarrhea, vomiting and peripheral neuropathy, and these are moderate and manageable. However, pulmonary toxicity is rarely reported to be associated with the FOLFOX regimen. Moreover, there is no established guideline for the management of this side effect. Here, along with a literature review, we report two cases of rapidly developing pulmonary fibrosis related to the use of the FOLFOX regimen in patients with colorectal carcinomas.